As per the latest report by IMARC Group, titled "Narcolepsy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the global narcolepsy drugs market size reached US$ 3.1 Billion in 2022. Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and sudden attacks of sleep. The advancements in medical science have led to the development of narcolepsy drugs that offer relief to those afflicted by this condition. These drugs are typically comprised of specific components that target the underlying causes of narcolepsy and help regulate sleep-wake cycles. Narcolepsy drugs primarily affect neurotransmitters in the brain, particularly those involved in regulating wakefulness and sleep. One common component found in these medications is Modafinil, a wake-promoting agent that stimulates the release of histamine, norepinephrine, dopamine, and other neurotransmitters. By increasing these neurotransmitters' levels, Modafinil helps promote wakefulness and reduce excessive daytime sleepiness in individuals with narcolepsy. The advantages of these drugs extend beyond alleviating excessive sleepiness, such as enhancing cognitive function, improving attention, and reducing the frequency of cataplexy attacks. Currently, different types of product variants are available to cater to specific needs and symptom severity, including methylphenidate and amphetamines, serotonin reuptake inhibitors (SSRIs), and norepinephrine reuptake inhibitors (NRIs).
Global Narcolepsy Drugs Market Trends:
The global market is primarily boosted by the increasing prevalence of narcolepsy. Moreover, rapid advancements in medical research and technology have led to the development of novel therapeutic options and a better understanding of the underlying mechanisms of narcolepsy, which is accelerating the market growth. Apart from this, the growing awareness among healthcare professionals and patients about the available treatment options and the importance of early diagnosis has contributed to the expansion of the market. Additionally, the presence of favorable reimbursement policies and government initiatives to improve the accessibility and affordability of narcolepsy drugs is fueling the market growth. The burgeoning geriatric population and the expanding pharmaceutical industry are also driving the market growth. In line with this, key players are investing in research and development (R&D) activities to introduce new and effective product variants, which is significantly impacting the market growth. The rising demand for personalized medicine and the development of tailored treatment approaches for narcolepsy are acting as other growth-inducing factors. Furthermore, the growing number of clinical trials and drug approvals for narcolepsy drugs, the rapid expansion of online platforms and e-commerce channels for drug distribution and sales, and strategic collaborations, partnerships, and mergers and acquisitions among pharmaceutical companies are propelling the market growth. Looking forward, the market value is projected to reach US$ 4.8 Billion by 2028, expanding at a CAGR of 7.51% during 2023-2028.
- By the type, the market is segregated into narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy.
- Based on the disease type, the market is divided into daytime extreme sleepiness, cataplexia, and others.
- By the therapeutic type, the market is segmented into sodium oxybate, central nervous system stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitor, and others.
- On the basis of the region, the market has been categorized into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the industry has also been examined with some of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis
||Type, Disease Type, Therapeutic Type, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800